Investors Exhibiting Increased Interest In Small Cap Stocks, Including CD International (CDII) And More

SALT LAKE CITY, UT / ACCESSWIRE / October 1, 2015 / With recent market fluctuations in play and some unexpected industries surging and tumbling, more and more investors are looking to small cap stocks as a way to enrich their portfolios. It can be difficult to navigate the field of small cap companies in order to determine where true potential lies, but one standout making some intriguing recent moves is CD International Enterprises (CDII). After placing an increased focus on industrial commodity distribution, CD International has reevaluated key partnerships and areas of interest with high revenue potential, and intends to place a larger emphasis on trading deals and business management.

In the last week alone, CD International entered into an agreement to acquire HK International Finance & Investment Group Limited, which focuses on hospitality, health endowment, and construction design, which posted over $6 million in consolidated net income in 2014. CD International is also working on trading deals involving copper concentrate and steel scrap. These deals could generate tens of millions in revenue in the near future.

Concurrently, the company expects to close on two transactions with APM Terminal at the beginning of 2016. APM is one of the world’s largest port owners, and CD International facilitated APM’s association with major port construction projects in Chile and Peru. Upon closing these transactions, CD international would be in line to receive a substantial consulting fee.

In recent months, CD International has shifted its focus away from legacy manufacturing in China so that the company could concentrate its efforts on monetizing its business networks that were developed through extensive experience in international markets like China and South America. The company estimates that the capital it will save by removing itself from legacy manufacturing, coupled with the revenue from consultation projects such as the one involving APM, could vastly improve its market share in the next one to two years.

CD International’s close association and prior experiences in the mineral and mining industry place the company in a unique position to evaluate industrial commodities, as its management group’s direct history in the field has informed many of its recent moves and acquisitions, establishing both a vast network in which to do business, and a willingness to act on the principles that have guided CD International to its present day status in the industry.

The bioscience and health and wellness sectors have also produced some recent, notable small cap stocks. ChromaDex Corp. (CDXC) has entered one of the trendier markets by padding their the natural supplement portfolio with Immulina, a spiraling extract said to enhance immune response.

Anavex Life Sciences Corp. (AVXL) focuses on drug development for Alzheimer’s, various cancers, and other central nervous system diseases. The company’s flagship medication is ANAVEX 2-73, which is currently in Phase 2a trials.

Taplmmune, Inc. (TPIV) also made headlines recently as the company owns the commercial rights to a vaccine used for Triple Negative Breast Cancer patients, that will soon be tested by Mayo Clinic. Mayo Clinic has just bee awarded a $13.3 million grant that will cover costs associated with the study.

Finally, Medical Marijuana, Inc. (MJNA) made progress on its goal to register a large number of medicinal marijuana products to pharmacies and healthcare professionals. Twelve of the company’s products received overseas registration and approval as international medical products, further legitimatizing the candidacy of these products as medicines.

As many of the aforementioned companies make moves that even major market contenders would be proud of, there may be no better time than the present to investigate small cap stocks. A multifaceted company like CD International, for instance, possesses several different ventures primed for revenue potential, proving that investors would be wise to take serious consideration of small cap stocks as a low-cost addition to their portfolios.

Seraphim Strategies is a third party publisher. Not a registered broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read http://tomorrowsbluechips.com/disclaimer/ This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

“Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

SOURCE: Seraphim Strategies LLC

ReleaseID: 432342